A target molecule for cancer therapy

Cancer Biology and Therapy

Volumn 6, Issue 4, 2007, Pages 481-486

  Singh, Ravibhushan ^a   Bandyopadhyay, Dilip ^a  

^a CANCER RESEARCH INSTITUTE   (India)

Author keywords

Extracellular domain; Hypoglycosyaltion; Immunotherapy; Immunotoxin; MUC1; Mucin; Recombinant antibody; Single chain antibody; Targeted therapy; Tumor target; Tumour associated antigen

Indexed keywords

MUCIN 1; CA 15-3 ANTIGEN; MONOCLONAL ANTIBODY;

CANCER THERAPY; GLYCOSYLATION; HUMAN; IMMUNE RESPONSE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; AMINO ACID SEQUENCE; BREAST TUMOR; DRUG EFFECT; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CA-15-3 ANTIGEN; FEMALE; GLYCOSYLATION; HUMANS; IMMUNOTHERAPY; MOLECULAR SEQUENCE DATA;

EID: 34548214630     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.4.4201     Document Type: Review

References (73)

1. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinoma is made up of tandem repeats. J Biol Chem 1988; 263:12820-3.
2. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, Pemberton L, Lalani EN, Wilson D. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990; 265:15286-93.
3. Baldus SE, Engelmann K, Hanisch FG. MUC1 and the MUCs: A family of human mucins with impact in cancer biology. Crit Rev Clin Lab Sci 2004; 41:189-231.
4. Dekker J, Rosen JWA, Buller HA, Einerhand AWC. The MUC family: An obituary. TRENDS in Biochem Sci 2002; 27:126-31.
5. Price MR. High molecular weight epithelial mucins as markers in breast cancer. Eur J Clin Oncol 1988; 24:1799.
6. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000; 95:286-93.
7. Noto H, Takahashi T, Makiguchi Y, Hayashi T, Hinoda Y, Imai K. Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin. Int Immunol 1997; 9:791-8.
8. Takahashi T, Makiguchi Y, Hinoda Y, Kakiuchi H, Nakagawa N, Imai K, Yachi A. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. J Immunol 1994; 153:2102-9.
9. Swallow DM, Gendler S, Griffiths B, Kearney A, Povey S, Sheer D, Palmer RW, Taylor-Papadimitriou J. The hypervariable gene locus PUM, which codes for the tumor associated epithelial mucins, is located on chromosome 1, within the region 1q21-24. Ann Hum Genet 1987; 51:289-94.
10. Swallow DM, Gendler S, Griffiths B, Corney G, Taylor-Papadimitriou J, Bramwell ME. The human tumor-associated epithelial mucins are coded by an expressed hypervariable gene locus PUM. Nature 1987; 328:82-84.
11. Apostolopoulos V, Ian F, McKenzie C. Cellular mucins: Targets for immunotherapy. Critical Reviews in Immunology 1994; 14:293-309.
12. Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M. MUC1 and cancer. Biochimica at Biophysica Acta 1999; 1455:301-13.
13. Cloosen S, Gratama J, van Leeuwen EB, Senden-Gijsbers BL, Oving EB, von Mensdorff-Pouilly S, Tarp MA, Mandel U, Clausen H, Germeraad WT, Bos GM. Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma. Br J Haematol 2006; 135:513-6.
14. Hanisch FG, Muller S. MUC1: The polymorphic appearance of a human mucin. Glycobiology 2000; 10:439-49.
15. Engelmann K, Baldus SE, Hanisch FG. Identification and topology of variant sequences within individual repeat domains of the human epithelial tumor mucin MUC1. J Biol Chem 2001; 276:27764-9.
16. Fontenot JD, Tjandra N, Bu D, Ho C, Montelaro RC, Finn OJ. Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (muc-1) protein core. Cancer Res 1993; 53:5386-94.
17. Burchell J, Gendler S, Taylor-Papadimitriou J, Girling A, Lewis A, Millis R, Lamport D. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 1987; 47:5476-82.
18. Bramwell ME, Wiseman G, Shotton DM. Electron-microscopic studies of the CA antigen, epitectin. J Cell Sci 1986; 86:249-61.
19. Hilkens J, Ligtenberg MJL, Vos HL, Litvinov SV. The structure of cell-associated mucin-like molecules and their adhesion modulating property. Trends Biochem Sci 1992; 17:359-63.
20. Ligtenberg MJ, Kruijshaar L, Buijs F, van Meijer M, Litvinov SV, Hilkens J. Cell-associated episialin is a complex containing two proteins derived from a common precursor. J Biol Chem 1992; 267:6171-7.
21. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 1995; 129:255-65.
22. Yamamoto M, Bharti A, Li Y, Kufe D. Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion. J Biol Chem 1997; 272:12492-4.
23. Schroeder JA, Thompson MC, Gardner MM, Gendler SJ. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem 2001; 276:13057-64.
24. Meerzaman D, Shapiro PS, Kim KC. Involvement of the MAP kinase ERK2 in MUC1 mucin signaling. Am J Physiol Lung Cell Mol Physiol 2001; 281:L86-91.
25. Zrihan-Licht S, Vos HL, Baruch A, Elroy-Stein O, Sagiv D, Keydar I, Hilkens J, Wreschner DH. Characterization and molecular cloning of a novel MUC1 protein, devoid of tandem repeats, expressed in human breast cancer tissue. Eur J Biochem 1994; 224:787-95.
26. Pandey P, Kharbanda S, Kufe D. Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. Cancer Res 1995; 55:4000-3.
27. Chardin P, Camonis JH, Gale NW, van Aelst L, Schlessinger J, Wigler MH, Bar-Sagi D. Human Sos1: A guanine nucleotide exchange factor for Ras that binds to GRB2. Science 1993; 260:1338-43.
28. Egan SE, Giddings BW, Brooks MW, Buday L, Sizeland AM, Weinberg RA. Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature 1993; 363:45-51.
29. Girling A, Bartkova J, Burchell J, Gendler S, Gillett C, Taylor-Papadimitriou J. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal anti-body SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer 1989; 43:1072-6.
30. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes. Int Immunol 1998; 10:1907-16.
31. Braga VM, Pemberton LF, Duhig T, Gendler SJ. Spatial and temporal expression of an epithelial mucin, Muc-1, during mouse development. Development 1992; 115:427-37.
32. Parry S, Hanisch FG, Leir SH, Sutton-Smith M, Morris HR, Dell A, Harris A. Glycosylation of the MUC1 mucin in epithelial cells and secretions. Glycobiology 2006; 16:623-34.
33. Trombetta ES, Helenius A. Lectins as chaperones in glycoprotein folding. Curr Opin Struct Biol 1998; 8:587-92.
34. Altschuler Y, Kinlough CL, Poland PA, Bruns JB, Apodaca G, Weisz OA, Hughey RP. Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state. Mol Biol Cell 2000; 11:819-31.
35. Litvinov SV, Hilkens J. The epithelial sialomucin, episialin, is sialylated during recycling. J Biol Chem 1993; 268:21364-71.
36. Nishimori I, Perini F, Mountjoy KP, Sanderson SD, Johnson N, Cerny RL, Gross ML, Fontenot JD, Hollingsworth MA. N-acetylgalactosamine glycosylation of MUC1 tandem repeat peptides by pancreatic tumor cell extracts. Cancer Res 1994; 54:3738-44.
37. Hilkens J. Biochemistry and function of mucins in malignant disease. Cancer Rev 1988; 11-12:25-54.
38. Brockhausen I, Yang JM, Burchell J, Whitehouse C, Taylor Papadimitriou J. Mechanism underlying aberrant glycosylation of MUC-1 mucin in breast cancer cells. Eur J Biochem 1995; 233:607-18.
39. Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M. MUC1 and cancer. Biochim Biophys Acta 1999; 1455:301-13.
40. Julian J, Carson DD. Formation of MUC1 metabolic complex is conserved in tumor-derived and normal epithelial cells. Biochem Biophys Res Commun 2002; 293:1183-90.
41. Metzgar RS, Rodriguez N, Finn OJ, Lan MS, Daasch VN, Fernsten PD, Meyers WC, Sindelar WF, Sandler RS, Seigler HF. Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma. Proc Natl Acad Sci USA 1984; 81:5242-6.
42. Reddish MA, MacLean GD, Poppema S, Berg A, Longenecker BM. Preimmunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother 1996; 42:303-9.
43. MacLean GD, Reddish MA, Longenecker BM. Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients. J Immunother 1997; 20:70-8.
44. Arai T, Fujita K, Fujime M, Irimura T. Expression of sialylated MUC1 in prostate cancer: Relationship to clinical stage and prognosis. Int J Urol 2005; 12:654-61.
45. Martoni A, Zamagni C, Bellanova B, Zanichelli L, Vecchi F, Cacciari N, Strocchi E, Pannuti F. CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: A prospective comparative study. Eur J Cancer 1995; 31A:1615-21.
46. Jerome KR, Barnd DL, Bendt KM, Boyer CM, Taylor-Papadimitriou J, McKenzie IF, Bast RC Jr, Finn OJ. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991; 51:2908-16.
47. Barnd DL, Lan MS, Metzgar RS, Finn OJ. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 1989; 86:7159-63.
48. Vlad AM, Muller S, Cudic M, Paulsen, Otvos Jr L, Hanisch FG, Finn OJ. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: Processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II- restricted T cells. J Exp Med 2002; 196:1435-46.
49. Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 1993; 151:3693-703.
50. Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ. Humoral immunity against a tandem repeat epitope of human mucin MUC1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994; 54:2856-60.
51. Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, Panageas K, Moynahan M, Houghton A, Norton L, Livingston PO. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 2000; 6:1693-701.
52. Finn OJ. Premalignant lesions as targets for cancer vaccines. J Exp Med 2003; 198:1623-6.
53. Karanikas V, Hwang LA, Pearson J, Ong CS, Apostolopoulos V, Vaughan H, Xing PX, Jamieson G, Pietersz G, Tait B, Broadbent R, Thynne G, McKenzie IF. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 1997; 100:2783-92.
54. Smith M, Burchell JM, Graham R, Cohen EP, Taylor-Papadimitriou J. Expression of B7.1 in MUC1-expressing mouse mammary epithelial tumor cell line inhibits tumorigenicity but does not induce autommunity in MUC1 transgenic mice. Immunology 1999; 97:648-55.
55. Wierecky J, Mueller M, Brossart P. Dendritic cell-based cancer immunotherapy targeting MUC-1. Cancer Immunol Immunother 2006; 55:63-7.
56. Pecher G, Haring A, Kaiser L, Thiel E. Mucin gene (MUC1) transfected dendritic cells as vaccine: Results of a phase I/II clinical trial. Cancer Immunol Immunother 2002; 51:669-73.
57. Lees CJ, Apostolopoulos V, Acres B, Ramshaw I, Ramsay A, Ong CS, McKenzie IF. Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice. Vaccine 2000; 19:158-62.
58. Mukherjee P, Madsen CS, Ginardi AR, Tinder TL, Jacobs F, Parker J, Agrawal B, Longenecker BM, Gendler SJ. Muc 1-specifc immunotherapy in a mouse model of spontaneous breast cancer. J Immunother 2003; 26:47-62.
59. Xing PX, Tjandra JJ, Stacker SA, Teh JG, Thompson CH, McLaughlin PJ, McKnzie IFC. Monoclonal antibodies reactive with mucin expressed in breast cancer. Immunol Cell Biol 1989; 67:183.
60. Mukherjee P, Ginardi AR, Madsen CS, Tinder TL, Jacobs F, Parker J, Agrawal B, Longenecker BM, Gendler SJ. MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment. Glycoconj J 2001; 18:931-42.
61. Yamamoto K, Ueno T, Kawaoka T, Hazama S, Fukui M, Suehiro Y, Hamanaka Y, Ikematsu Y, Imai K, Oka M, Hinoda Y. MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res 2005; 25:3575-9.
62. McKolanis JR, Pecher G, Lotze MJ, Finn OJ. Mucin reactive CTL induced by in vivo immunization. Proc Amer Assoc Cancer Res 1996; 37:466.
63. Gong J, Chen D, Kashiwaba M, Li Y, Chen L, Takeuchi H, Qu H, Rowse GJ, Gendler SJ, Kufe D. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA 1998; 95:6279-83.
64. Gong J, Avigan D, Chen D, Wu Z, Koido S, Kashiwaba M, Kufe D. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 1998; 97:2715-8.
65. Gong J, Apostolopoulos V, Chen D, Chen H, Koido S, Gendler SJ, McKenzie IF, Kufe D. Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells. Immunology 2000; 101:316-24.
66. Price MR, Rye PD, Petrakou E, Murray A, Brady K, Imai S, Haga S, Kiyozuka Y, Schol D, Meulenbroek MF, Snijdewint FG, von Mensdorff-Pouilly S, Verstraeten RA, Kenemans P, Blockzjil A, Nilsson K, Nilsson O, Reddish M, Suresh MR, Koganty RR, Fortier S, Baronic L, Berg A, Longenecker MB, Hilgers J. Summary report on the ISOBM TD-4 Workshop: Analysis of 56 monoclonal antibodies against the MUC1 mucin. Tumor Biol 1998; 19:1-20.
67. Wierecky J, Muller MR, Wirths S, Halder-Oehler E, Dorfel D, Schmidt SM, Hantschel M, Brugger W, Schroder S, Horger MS, Kenz L, Brossart P. Immunologic and clinical responses after vaccination with peptide pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 2006; 66:5910-8.
68. MacLean GD, Bowen-Yacyshyn MB, Samuel J, Meikle A, Stuart G, Nation J, Poppema S, Jerry M, Koganty R, Wong T. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J Immunother 1992; 11:292-305.
69. MacLean GD, Reddish M, Koganty RR, Wong T, Gandhi S, Smolenski M, Samuel J, Nabholtz JM, Longenecker BM. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother 1993; 36:215-22.
70. Holmber LA, Sandmaier BM. Vaccination with theratope (STn-KLH) as treatment for breast cancer. Expert Rev Vaccines 2004; 3:655-63.
71. Hird V, Maraveyas A, Snook D, Dhokia B, Soutter WP, Meares C, Stewart JS, Mason P, Lambert HE, Epenetos AA. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993; 68:403-6.
72. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992; 52:3402-8.
73. Singh R, Samant U, Hyland S, Chaudhari PR, Wels WS, Bandyopadhyay D. Target specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors. Mol Cancer Ther 2007; 6:562-9.